BACKGROUND: Patients taking oral anticoagulant therapy balance the risks of hemorrhage and thromboembolism. We sought to determine the association between anticoagulation intensity and the risk of hemorrhagic and thromboembolic events. We also sought to determine how under-or overanticoagulation would influence patient outcomes. METHODS: We reviewed the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL databases to identify studies involving patients taking anticoagulants that reported person-years of observation and the number of hemorrhages or thromboemboli in 3 or more discrete ranges of international normalized ratios. We estimated the overall relative and absolute risks of events specific to anticoagulation intensity. RESULTS: We included 19 studies. The risk of hemorrhage increased significantly at high international normalized ratios. Compared with the therapeutic ratio of 2-3, the relative risk (RR) of hemorrhage (and 95% confidence intervals [CIs]) were 2.7 (1.8-3.9; p < 0.01) at a ratio of 3-5 and 21.8 (12.1-39.4; p < 0.01) at a ratio greater than 5. The risk of thromboemboli increased significantly at ratios less than 2, with a relative risk of 3.5 (95% CI 2.8-4.4; p < 0.01). The risk of hemorrhagic or thromboembolic events was lower at ratios of 3-5 (RR 1.8, 95% CI 1.2-2.6) than at ratios of less than 2 (RR 2.4, 95% CI 1.9-3.1; p = 0.10). We found that a ratio of 2-3 had the lowest absolute risk (AR) of events (AR 4.3%/yr, 95% CI 3.0%-6.3%). CONCLUSIONS: The risks of hemorrhage and thromboemboli are minimized at international normalized ratios of 2-3. Ratios that are moderately higher than this therapeutic range appear safe and more effective than subtherapeutic ratios.
BACKGROUND:Patients taking oral anticoagulant therapy balance the risks of hemorrhage and thromboembolism. We sought to determine the association between anticoagulation intensity and the risk of hemorrhagic and thromboembolic events. We also sought to determine how under-or overanticoagulation would influence patient outcomes. METHODS: We reviewed the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL databases to identify studies involving patients taking anticoagulants that reported person-years of observation and the number of hemorrhages or thromboemboli in 3 or more discrete ranges of international normalized ratios. We estimated the overall relative and absolute risks of events specific to anticoagulation intensity. RESULTS: We included 19 studies. The risk of hemorrhage increased significantly at high international normalized ratios. Compared with the therapeutic ratio of 2-3, the relative risk (RR) of hemorrhage (and 95% confidence intervals [CIs]) were 2.7 (1.8-3.9; p < 0.01) at a ratio of 3-5 and 21.8 (12.1-39.4; p < 0.01) at a ratio greater than 5. The risk of thromboemboli increased significantly at ratios less than 2, with a relative risk of 3.5 (95% CI 2.8-4.4; p < 0.01). The risk of hemorrhagic or thromboembolic events was lower at ratios of 3-5 (RR 1.8, 95% CI 1.2-2.6) than at ratios of less than 2 (RR 2.4, 95% CI 1.9-3.1; p = 0.10). We found that a ratio of 2-3 had the lowest absolute risk (AR) of events (AR 4.3%/yr, 95% CI 3.0%-6.3%). CONCLUSIONS: The risks of hemorrhage and thromboemboli are minimized at international normalized ratios of 2-3. Ratios that are moderately higher than this therapeutic range appear safe and more effective than subtherapeutic ratios.
Authors: A J Azar; S C Cannegieter; J W Deckers; E Briët; P F van Bergen; J J Jonker; F R Rosendaal Journal: J Am Coll Cardiol Date: 1996-05 Impact factor: 24.094
Authors: A J Azar; J W Deckers; F R Rosendaal; P F van Bergen; F J van der Meer; J J Jonker; E Briët Journal: Thromb Haemost Date: 1994-09 Impact factor: 5.249
Authors: S C Cannegieter; F R Rosendaal; A R Wintzen; F J van der Meer; J P Vandenbroucke; E Briët Journal: N Engl J Med Date: 1995-07-06 Impact factor: 91.245
Authors: Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Trevor J Wilkieson; Alistair J Ingram; Mark A Crowther; Steven D Soroka; Ryuta Nagai; Kailash K Jindal; Catherine M Clase Journal: Clin J Am Soc Nephrol Date: 2011-04-14 Impact factor: 8.237
Authors: Eric Q Wu; Jipan Xie; Chun Wu; Ella Xiaoyan Du; Nanxin Li; Ruoding Tan; Yuanli Liu Journal: Pharmacoeconomics Date: 2014-03 Impact factor: 4.981
Authors: Anton Pottegård; Peter M Meegaard; Line H V Holck; Rene dePont Christensen; Hanne Madsen; Jesper Hallas Journal: Eur J Clin Pharmacol Date: 2012-07-31 Impact factor: 2.953
Authors: Alexandra Papaioannou; Courtney C Kennedy; Glenda Campbell; Jacqueline B Stroud; Luqi Wang; Lisa Dolovich; Mark A Crowther Journal: BMC Geriatr Date: 2010-06-10 Impact factor: 3.921